Albert C Shaw, MD, PhD
Professor of Medicine (Infectious Diseases)DownloadHi-Res Photo
Cards
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAbout
Copy Link
Titles
Professor of Medicine (Infectious Diseases)
Biography
Dr. Shaw is a graduate of Harvard College who completed his M.D. training at Harvard Medical School and his Ph.D. in the laboratory of Philip Leder. After completing his clinical training in Internal Medicine and Infectious Diseases at Massachusetts General Hospital, he was a postdoctoral fellow in the laboratory of Fred Alt. Dr. Shaw joined the faculty at Yale in 2001, and is currently Professor of Medicine in the Section of Infectious Diseases. His research focuses on the immunology of aging, and his laboratory has interests in age-associated alterations in innate immune function and vaccine response in humans, as well as circadian regulation of immune response and mechanisms of inflammatory dysregulation in medication-associated treatment of opioid use disorder. He was a Howard Hughes Postdoctoral Physician Research Fellow, Brookdale National Fellow, and T. Franklin Williams Scholar, and he is a Fellow of the Infectious Disease Society of America and member of the Interurban Clinical Club.
Last Updated on April 07, 2025.
Appointments
Infectious Diseases
ProfessorPrimary
Other Departments & Organizations
- Center for Infection and Immunity
- Claude D. Pepper Older Americans Independence Center
- CPIRT - Center for Pulmonary Injury, Inflammation, Repair and Therapeutics
- Human and Translational Immunology Program
- Infectious Diseases
- Internal Medicine
- Rheumatic Diseases Research Core
- Yale Center for Research on Aging (Y-Age)
- Yale Medicine
- Yale New Haven Health System
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
Education & Training
- Fellow
- Massachusetts General Hospital (1997)
- Intern and Resident
- Massachusetts General Hospital (1994)
- PhD
- Harvard University (1991)
- MD
- Harvard Medical School (1991)
- AB
- Harvard College (1983)
Research
Copy Link
Overview
Medical Research Interests
Aging; DNA Repair; Immune System; Immunity, Innate; Infectious Disease Medicine; Influenza Vaccines; Toll-Like Receptors
ORCID
0000-0003-4970-7640
Research at a Glance
Yale Co-Authors
Frequent collaborators of Albert C Shaw's published research.
Publications Timeline
A big-picture view of Albert C Shaw's research output by year.
Research Interests
Research topics Albert C Shaw is interested in exploring.
Ruth R Montgomery, PhD
Steven Kleinstein, PhD
David A. Hafler, MD, FANA, MSc
Akiko Iwasaki, PhD
Albert Icksang Ko, MD
Subhasis Mohanty, PhD
81Publications
8,914Citations
Aging
Immunity, Innate
Influenza Vaccines
Toll-Like Receptors
Immune System
Publications
2026
Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging
Mishra M, Kim H, Youm Y, Gonzalez-Hurtado E, Zaitsev K, Dlugos T, Shchukina I, Gliniak C, Ravussin E, Mohanty S, Shaw A, Scherer P, Artyomov M, Dixit V. Exoproteome of calorie-restricted humans identifies complement deactivation as an immunometabolic checkpoint reducing inflammaging. Nature Aging 2026, 1-15. PMID: 41974968, DOI: 10.1038/s43587-026-01107-0.Peer-Reviewed Original ResearchCitationsAltmetricConceptsExtracellular signal-regulated kinaseCaloric restrictionComplement pathwayPhospholipase A2 group VIIAge-related inflammationSignal-regulated kinaseCALERIE trialFibroblast growth factor 21Macrophage subsetsVisceral fatReduce inflammagingAutocrine signalingC3a/C3 ratioPlasma samplesMiceInflammagingInflammationEffects of CRAgeGroup VIIC3aComplementHuman agingDiverse organismsPathwayEmpiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19
Glascock A, Maguire C, Phan H, Lydon E, Schaenman J, Calfee C, Melamed E, Greenland J, Corry D, Kheradmand F, Baden L, Sekaly R, McComsey G, Haddad E, Cairns C, Geng L, Pulendran B, Fernandez-Sesma A, Simon V, Metcalf J, Agudelo Higuita N, Messer W, Davis M, Nadeau K, Kraft M, Bime C, Erle D, Atkinson M, Brakenridge S, Ehrlich L, Montgomery R, Shaw A, Hough C, Hafler D, Augustine A, Becker P, Peters B, Ozonoff A, Hoch A, Kim-Schulze S, Krammer F, Bosinger S, Eckalbar W, Altman M, Wilson M, Guan L, Maecker H, Steen H, Diray-Arce J, Rouphael N, Kleinstein S, Jayavelu N, Reed E, Levy O, Chu V, Langelier C. Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19. Nature Microbiology 2026, 11: 1100-1112. PMID: 41840216, PMCID: PMC13056551, DOI: 10.1038/s41564-026-02285-8.Peer-Reviewed Original ResearchCitationsAltmetricConceptsUpper respiratory microbiomeRespiratory microbiomeAnti-inflammatory benefitsPatients treated with azithromycinProspective multicentre cohortViral respiratory infectionsSystemic immune responsesAssociated with commensalismInflammatory gene expressionResistance gene expressionAzithromycin treatmentMulticentre cohortGene expressionRespiratory infectionsAzithromycinHospitalized patientsImmune responsePatientsNasal swabsAntibioticsPotential pathogensCOVID-19Microbiome compositionResistance genesExpressionScience for vaccine policy: Lack of transparency, misinformation, and poor decision processes at the December 2025 ACIP meeting
Loehr J, Moser C, Asturias E, Shaw A, Goddard K, Chen L, Chu H, Kamboj M, Hawkinson D, Maldonado Y, Talbot H, Brewer N. Science for vaccine policy: Lack of transparency, misinformation, and poor decision processes at the December 2025 ACIP meeting. Vaccine 2026, 76: 128338. PMID: 41719792, DOI: 10.1016/j.vaccine.2026.128338.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBirth dose of hepatitis B vaccineDoses of hepatitis B vaccineImmunization PracticesThematic analysisHepatitis B infectionRate of hepatitis B infectionHepatitis B vaccineVaccination policyBirth doseB infectionACIP membersB vaccineFramework analysisInadequate preparationEpidemiological dataAssociated diseasesACIPPublic healthThe Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025
Asturias E, Schechter R, Talbot H, Boom J, Brooks O, Chen L, Chu H, Cineas S, Hawkinson D, Kamboj M, Loehr J, Lyons K, Maldonado Y, Moser C, Roberts M, Shaw A, Wiley Z, Zucker J, Brewer N. The Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025. Clinical Infectious Diseases 2026, ciag042. PMID: 41607311, DOI: 10.1093/cid/ciag042.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDiminished credibilityEvidence-based immunization policyU.S. leadershipStructural reformsPillars of public healthPublic trustVoting membersDepartment of HealthAdvisory capacityPolicyPublic healthU.S.Abrupt replacementPoliticizationPotential consequencesRaised concernsGovernmentReformRestructuringHealthDeliberationScientific rigorLeadershipNormsAdvisory CommitteeMachine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
Doni Jayavelu N, Samaha H, Wimalasena S, Hoch A, Gygi J, Gabernet G, Ozonoff A, Liu S, Milliren C, Levy O, Baden L, Melamed E, Ehrlich L, McComsey G, Sekaly R, Cairns C, Haddad E, Schaenman J, Shaw A, Hafler D, Montgomery R, Corry D, Kheradmand F, Atkinson M, Brakenridge S, Agudelo Higuit N, Metcalf J, Hough C, Messer W, Pulendran B, Nadeau K, Davis M, Geng L, Fernandez Sesma A, Simon V, Krammer F, Kraft M, Bime C, Calfee C, Erle D, Langelier C, Guan L, Maecker H, Peters B, Kleinstein S, Reed E, Augustine A, Diray-Arce J, Becker P, Rouphael N, Altman M. Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors. Communications Medicine 2026, 6: 1. PMID: 41484172, PMCID: PMC12764860, DOI: 10.1038/s43856-025-01230-w.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAntibody titersBaseline clinical characteristicsViral load measurementsLong-term public health impactHospital admissionAcute COVID-19Low antibody titersMethodsClinical dataViral loadClinical characteristicsImmunological factorsClinical dataFemale sexEstablished biomarkersImpact of SARS-CoV-2Risk factorsSignificant health issueSub-phenotypesPatient outcomesDiagnostic precisionAUROC valuesSARS-CoV-2Post-acute sequelaeInfected individualsDisease mechanisms
2025
Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions
Jamwal S, Calhoun C, Mohanty S, Montgomery R, Krishnamurti L, Shaw A, Yildirim I. Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions. Immunology 2025, 177: 445-456. PMID: 41387179, PMCID: PMC12826409, DOI: 10.1111/imm.70080.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMemory B cellsSickle cell diseaseImmune dysregulationT cellsB cellsChronic inflammationImmunological enigmaImmune activationClass-switched memory B cellsAntigen-specific T cell responsesAntigen-specific T cellsImmune responseCell diseaseAntigen-specific immune activationAntigen-specific immune responsesImmune-targeted therapiesSickle cell disease patientsT-cell countsT-cell abnormalitiesT-cell phenotypeMemory B cell differentiationT cell responsesB cell compartmentAdaptive immune dysfunctionSickle cell disease pathophysiologyEvaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study
Abe K, Holmes T, Nguyen T, Abe K, Holmes T, Nguyen T, Kim-Schulze S, Levy O, Baden L, Melamed E, Ehrlich L, McComsey G, Sekaly R, Cairns C, Haddad E, Shaw A, Hafler D, Montgomery R, Corry D, Kheradmand F, Atkinson M, Brakenridge S, Higuita N, Metcalf J, Hough C, Messer W, Pulendran B, Nadeau K, Davis M, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Calfee C, Erle D, Schaenman J, Reed E, Ozonoff A, Peters B, Kleinstein S, Augustine A, Diray-Arce J, Becker P, Rouphael N, Maecker H, Kim-Schulze S, Levy O, Baden L, Melamed E, Ehrlich L, McComsey G, Sekaly R, Cairns C, Haddad E, Shaw A, Hafler D, Montgomery R, Corry D, Kheradmand F, Atkinson M, Brakenridge S, Higuita N, Metcalf J, Hough C, Messer W, Pulendran B, Nadeau K, Davis M, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Calfee C, Erle D, Schaenman J, Reed E, Ozonoff A, Peters B, Kleinstein S, Augustine A, Diray-Arce J, Becker P, Rouphael N, Maecker H. Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study. The Journal Of Immunology 2025, 214: 3310-3320. PMID: 41166719, PMCID: PMC12726064, DOI: 10.1093/jimmun/vkaf263.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsScience for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes
Asturias E, Chen L, Shaw A, Moser C, Maldonado Y, Zucker J, Chu H, Talbot H, Cineas S, Lyons K, Schechter R, Kamboj M, Wiley Z, Brewer N. Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes. Vaccine 2025, 67: 127876. PMID: 41135287, DOI: 10.1016/j.vaccine.2025.127876.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsBirth doseBirth dose of hepatitis B vaccineDoses of hepatitis B vaccineHepatitis B vaccineVaccine policy recommendationsVaccination policyMMRV vaccineB vaccineSafety dataVaccination recommendationsClinical decision makingImmunization PracticesVaccine implementationACIPApplication of standardized protocolsIndependent reviewersCOVID-19 vaccineMaturation rateVaccineStandard protocolCirculating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS
Costa Monteiro A, Pickering H, Sarma A, Taylor C, Jenkins M, Hsu F, Nadel B, Levy O, Baden L, Melamed E, Ehrlich L, McComsey G, Sekaly R, Cairns C, Haddad E, Shaw A, Hafler D, Montgomery R, Corry D, Kheradmand F, Atkinson M, Brakenridge S, Higuita N, Metcalf J, Hough C, Messer W, Pulendran B, Nadeau K, Davis M, Geng L, Fernandez-Sesma A, Simon V, Krammer F, Kraft M, Bime C, Calfee C, Erle D, Bosinger S, Eckalbar W, Maecker H, Rahman A, Guan L, Peters B, Kleinstein S, Augustine A, Diray-Arce J, Becker P, Rouphael N, Agus M, Kulkarni H, Schaenmann J, Salehi-Rad R, Matthay M, Reed E, Sapru A. Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS. Critical Care 2025, 29: 432. PMID: 41088445, PMCID: PMC12522733, DOI: 10.1186/s13054-025-05596-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRespiratory failureNon-invasive evaluationEndothelial damageNon-survivorsRespiratory outcomesInvasive mechanical ventilationAdult hospitalized patientsMultivariate logistic regressionAssociated with mortalityPresence of endothelial cellsRespiratory trajectoriesPediatric patientsValidation cohortMechanical ventilationCell signaturesPrimary outcomeMethodsTo testEndothelial cellsCOVID-19 non-survivorsPatientsProteomic phenotypesLogistic regressionARDSOutcomesBaselineA multi-omics recovery factor predicts long COVID in the IMPACC study
Gabernet G, Maciuch J, Gygi J, Moore J, Hoch A, Syphurs C, Chu T, Jayavelu N, Corry D, Kheradmand F, Baden L, Sekaly R, McComsey G, Haddad E, Cairns C, Rouphael N, Fernandez-Sesma A, Simon V, Metcalf J, Higuita N, Hough C, Messer W, Davis M, Nadeau K, Pulendran B, Kraft M, Bime C, Reed E, Schaenman J, Erle D, Calfee C, Atkinson M, Brakenridge S, Melamed E, Shaw A, Hafler D, Augustine A, Becker P, Ozonoff A, Bosinger S, Eckalbar W, Maecker H, Kim-Schulze S, Steen H, Krammer F, Westendorf K, Network I, Peters B, Fourati S, Altman M, Levy O, Smolen K, Montgomery R, Diray-Arce J, Kleinstein S, Guan L, Ehrlich L. A multi-omics recovery factor predicts long COVID in the IMPACC study. Journal Of Clinical Investigation 2025, 135: e193698. PMID: 40924481, PMCID: PMC12582403, DOI: 10.1172/jci193698.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSARS-CoV-2 infectionCOVID-19 patientsMulti-OmicsSARS-CoV-2Risk of LCAcute COVID-19 severityImmune profiling dataSubset frequenciesBiomarkers of LCPlasma metabolomeCOVID-19 severityPotential treatment targetPBMC transcriptomesClinical parametersBiological underpinningsStress erythropoiesisCell frequencyInflammatory mediatorsLC biomarkersTherapeutic opportunitiesHospital dischargeAndrogenic steroidsDisease severityTreatment targetPatients
Clinical Trials
Current Trials
Impact of HIV Infection on Immunologic, Transcriptomic, and Metabolomic Signatures
IRB ID1608018239RoleSub InvestigatorPrimary Completion Date09/01/2021Recruiting ParticipantsGenderBothAge18+ years
Clinical Care
Copy Link
Overview
Albert C. Shaw, MD, PhD, is an infectious diseases specialist who provides care for individuals with a variety of infections, including those that affect older adults. He focuses on how age-related changes in the body’s defenses can make people more vulnerable to infection and immune system complications.
As a professor of medicine at Yale School of Medicine, Dr. Shaw studies the ways in which the immune system’s first line of defense, called the innate immune system, changes with age. This includes investigating how these shifts might reduce vaccine effectiveness and contribute to ongoing, low-grade inflammation that can harm overall health. He also examines how circadian rhythms—biological processes that follow a 24-hour cycle—may regulate immune responses, as well as how certain treatments for opioid use disorder might influence inflammation.
Dr. Shaw earned his medical degree from Harvard Medical School and completed a doctorate at Harvard University. He then pursued an internal medicine residency and an infectious diseases fellowship at Massachusetts General Hospital.
Clinical Specialties
Infectious Diseases
Fact Sheets
Influenza (Flu)
Learn More on Yale MedicineMRSA and Drug-Resistant Microbes
Learn More on Yale MedicineCOVID-19
Learn More on Yale MedicineCoronavirus
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews
Copy Link
News
- October 15, 2025Source: Everyday Health
Bird Flu Risk: What's the Level of Threat?
- August 27, 2025
Yale Pepper Center Seeks Letters of Intent For Aging Research 2025 - 2026
- February 19, 2025Source: MSN
Is Now the Time to Really Worry About Bird Flu?
- November 19, 2024Source: Yahoo
What are the symptoms of foodborne illnesses like E. coli? What to know amid a new carrot recall.
Get In Touch
Copy Link
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.